Molly Sherwood, AHF’s Director of Research, presented on emerging treatments for HDFN at the 2024 Association for Advancements of Blood and Biotherapies (AABB) meeting in Houston, Texas. Molly discussed patient perspectives on the treatability of HDFN and new clinical trial results on nipocalimab for early onset severe HDFN and darbepoetin alfa for the reduction in number of transfusions in neonates with HDFN. She also presented the methodology for upcoming best practice guideline development for blood product selection for females with life-threatening hemorrhage and treatment HDFN.

Pictured above is Caroline Wesonga, National Blood Ambassador to Kenya; Molly Sherwood, Director of Research for Allo Hope Foundation; Dr. Meghan Delaney, President of AABB; and Asma Aliawadh, Medical Officer of Health for Langata and Kibera Sub-Counties in Kenya